TEST#1 RETEST #2: Femara® gains U.S. FDA approval as only post-tamoxifen treatment for early breast cancer

Contacts

 

John Gilardi
Novartis Global Media Relations
Tel +41 61 324 3018 (direct)
or  +41 79 596 1408 (mobile)
john.gilardi@group.novartis.com

 

Kim Fox
Novartis Pharma Communications
+1 862 778 7692 (direct)
+1 917 415 2425 (mobile)
kim.fox@pharma.novartis.com

 

 

Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2003, the Group's businesses achieved sales of USD 24.9 billion and a net income of USD 5.0 billion. The Group invested approximately USD 3.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 80,000 people and operate in over 140 countries around the world. For further information please consult http://www.novartis.com.

 

Additional information regarding Femara or Novartis Oncology can be found on the websites www.femara.com or www.novartisoncology.com. Additional media information can be found at www.novartisoncologyvpo.com.